Abstract
Treatment guidelines for hypercholesterolemic patients identify low-density lipoprotein cholesterol (LDL-C) as the primary treatment target with non–high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein (apo) B as secondary targets of therapy. Statin monotherapy lowers LDL-C and non-HDL-C to a much greater extent than apoB; thus, statin-treated patients may remain at increased coronary risk due to elevated levels of apoB-containing particles.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
